JAGSONPAL PHARMACEUTICALS
JAGSNPHARM · General/Diversified · NSE
₹210
Current Market Price
Fair Value (DCF)
₹109
Discount to FV
-48.1%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
4/9
Economic Moat
Wide
Confidence
50%
ROE
15.6%
Debt/Equity
0.03
WACC
11.1%
Market Cap
₹1,407 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
23.9%
Return on capital employed
EV / EBITDA
18.1×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
73.8×
EBIT covers interest
Current Ratio
6.22×
Short-term liquidity
Asset Turnover
1.03×
Revenue per ₹ of assets
Revenue CAGR (3Y)
6.7%
3-year revenue growth
Revenue CAGR (5Y)
8.8%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹209.63
Bear case
Discount -253.8%
Base case
Discount -92.6%
Bull case
Discount -60.5%
Ratio Trends
JAGSNPHARM · last 8 annual periods
ROE
15.6%
ROCE
23.9%
Operating Margin
—
Debt / Equity
0.03×
PE
28.7×
EV / EBITDA
18.1×
Historical Financials
JAGSNPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹226 Cr | ₹237 Cr | ₹209 Cr | ₹269 Cr | ₹287 Cr | +6.2% |
| EBITDA | ₹28.4 Cr | ₹36.3 Cr | ₹32.3 Cr | ₹78.9 Cr | ₹68.0 Cr | +24.4% |
| EBIT | ₹27.6 Cr | ₹35.2 Cr | ₹30.7 Cr | — | — | +2.7% |
| PAT | ₹19.6 Cr | ₹26.7 Cr | ₹22.5 Cr | ₹55.4 Cr | ₹43.1 Cr | +21.8% |
| EPS (diluted) | ₹7.48 | ₹10.20 | ₹8.46 | — | — | +3.1% |
| CFO | ₹5.6 Cr | ₹46.7 Cr | ₹35.2 Cr | ₹55.1 Cr | ₹46.8 Cr | +70.1% |
| CapEx | ₹-1.0 Cr | ₹-0.3 Cr | ₹-0.2 Cr | ₹-0.3 Cr | ₹-0.1 Cr | — |
| FCF | ₹5.9 Cr | ₹46.3 Cr | ₹34.9 Cr | ₹54.8 Cr | ₹46.7 Cr | +67.9% |
| Total Assets | ₹164 Cr | ₹195 Cr | ₹217 Cr | ₹278 Cr | ₹317 Cr | +17.8% |
| Total Debt | ₹0.0 Cr | ₹6.0 Cr | ₹8.9 Cr | ₹9.2 Cr | ₹8.2 Cr | — |
| Shareholders' Equity | ₹133 Cr | ₹159 Cr | ₹187 Cr | ₹240 Cr | ₹276 Cr | +20.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JAGSNPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 SAKAR SAKAR | — | — | Pending | 6.1% | — |
SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
BETA BETA | — | — | Pending | 16.9% | — |
 VENUSREM VENUSREM | — | — | Pending | 8.1% | — |
 BAJAJHCARE BAJAJHCARE | — | — | Pending | 3.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹8.50/sh
Last payout
2025-09-12
₹2.50
Peak payout
₹2.50
Trailing yield
1.19%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. JAGSONPAL PHARMACEUTICALS (JAGSNPHARM.NS) trades at 209.63 vs a model fair value of 108.83, a gap of -48.1%. Piotroski F-score: 4/9. Moat...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of JAGSNPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JAGSNPHARM →
Compare
Head-to-head with peers
Compare JAGSNPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JAGSNPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.